公司概述
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical entity dedicated to the development and commercialization of therapies aimed at enhancing visual acuity within the United States market. The company functions within the healthcare sector, specifically targeting the biotechnology industry, which implies a focus on high-risk, high-reward research and development activities with significant regulatory hurdles. In terms of scale, the company holds a market capitalization of $291.28 million, generates annual revenue of $19.09 million, and employs 152 individuals to execute its operational strategy. These financial figures indicate that LENZ is a mid-cap biotechnology firm with a relatively small revenue base, suggesting it is likely in a growth or commercialization phase where capital allocation is critical for product advancement rather than profit maximization.
财务健康
The company reported a revenue of $19.09 million over the trailing twelve months, yet recorded a net income of -$82,127,000 and an EBITDA of -$90,851,000. The substantial gap between positive revenue and deeply negative net income reveals a cost structure heavily weighted toward research, development, and general administrative expenses typical of early-to-mid stage biotechnology companies. Free cash flow stands at -$40,249,248, indicating that the company is burning cash to fund its operations and product pipeline, which limits immediate financial flexibility but is often necessary for achieving commercial milestones. The gross margin is an impressive 97.8%, reflecting the high value of intangible drug products, while the operating margin of -2422.1% and profit margin of 0.0% highlight the severe losses incurred before considering interest and other financing costs. On the liability side, the company holds $292.35 million in cash against only $815,000 in debt, supported by a debt-to-equity ratio of 0.29, which suggests a balance sheet that is highly conservative and well-capitalized relative to its obligations. Liquidity is further evidenced by a current ratio of 14.23, indicating an extremely strong ability to meet short-term liabilities with current assets. However, the return on equity of -33.6% and return on assets of -21.9% demonstrate that management has not yet generated positive returns on the capital invested, a common characteristic for firms still developing their core therapeutic assets.
估值评估
The trailing twelve-month P/E ratio is listed as N/A due to the lack of net income, while the forward P/E is -3.53, a metric that implies the market is pricing in future earnings growth that has not yet materialized. The price-to-book ratio is 1.02, indicating that the market values the company at slightly more than its book value, suggesting investors are placing a small premium on the potential of its product candidates. Alternative valuation metrics include a price-to-sales ratio of 15.26 and an EV/EBITDA of 0.00, which suggest the company is valued significantly on its revenue generation potential rather than profitability, a standard practice for loss-making biotech firms. The stock has traded between a 52-week high of $50.40 and a 52-week low of $8.25, showing extreme price volatility over the past year. The beta value of 2.29 indicates that the stock is highly volatile and is expected to move with greater magnitude than the broader market, reflecting the inherent risks associated with the biotechnology sector.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, meaning there is insufficient historical data in the current reporting period to calculate a definitive growth rate or compare earnings expansion against revenue expansion. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the firm reinvests all available earnings and cash flow back into research and development rather than distributing income to shareholders. This reinvestment strategy is typical for companies in the development phase that prioritize product pipeline expansion over immediate shareholder returns. Overall, the growth and income profile of LENZ is characterized by significant cash consumption to fund operations, a lack of current profitability, and a reliance on future commercialization success to drive value creation for shareholders.